{
    "organizations": [],
    "uuid": "fdc303b932be41ef0d828a01418b32531fd000c2",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-fda-accepts-turnstone-biologics-in/brief-fda-accepts-turnstone-biologics-ind-for-cancer-immunotherapy-idUSASC0A2KI",
    "ord_in_thread": 0,
    "title": "BRIEF-FDA Accepts Turnstone Biologics' IND For Cancer Immunotherapy",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 16 (Reuters) - Turnstone Biologics:\n* TURNSTONE BIOLOGICS ANNOUNCES U.S. FDA ACCEPTANCE OF IND FOR IMMUNOTHERAPY TARGETING HPV POSITIVE CANCERS\n* TURNSTONE BIOLOGICS ANNOUNCES U.S. FDA ACCEPTANCE OF IND FOR IMMUNOTHERAPY TARGETING HPV POSITIVE CANCERS\n* TURNSTONE BIOLOGICS - ENTERED INTO A CLINICAL SUPPLY AGREEMENT WITH F. HOFFMANN-LA ROCHE LTD UNDER WHICH ROCHE WILL PROVIDE ATEZOLIZUMAB (TECENTRIQ) Source text for Eikon:\n ",
    "published": "2018-05-16T19:47:00.000+03:00",
    "crawled": "2018-05-17T14:51:38.007+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "turnstone",
        "biologics",
        "turnstone",
        "biologics",
        "announces",
        "fda",
        "acceptance",
        "ind",
        "immunotherapy",
        "targeting",
        "hpv",
        "positive",
        "cancer",
        "turnstone",
        "biologics",
        "announces",
        "fda",
        "acceptance",
        "ind",
        "immunotherapy",
        "targeting",
        "hpv",
        "positive",
        "cancer",
        "turnstone",
        "biologics",
        "entered",
        "clinical",
        "supply",
        "agreement",
        "roche",
        "ltd",
        "roche",
        "provide",
        "atezolizumab",
        "tecentriq",
        "source",
        "text",
        "eikon"
    ]
}